ASCO 2021: Updates in Myeloproliferative Neoplasms | Supplements And Featured Publications

This publication covers a multitude of presentations in myeloproliferative neoplasms that were presented and discussed during the 2021 ASCO Annual Meeting.

Symptom Improvement Appears Similar With Momelotinib Vs Ruxolitinib in Myelofibrosis

June 17, 2021

Momelotinib can provide clinically relevant and comparable improvement in overall symptom burden and individual symptom items compared with ruxolitinib in patients with intermediate- and high-risk JAK inhibitor–naïve myelofibrosis.

Week 24 Transfusion Independence With Momelotinib Is Associated With Improved OS in Myelofibrosis

June 10, 2021

Week 24 transfusion independence was associated with an improvement in overall survival vs week 24 transfusion dependence in patients with myelofibrosis who were randomized to momelotinib in the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials.